| Attribute |
Value |
| 52 Week Change |
-0.492891 |
| Address1 |
Essener Bogen 7 |
| All Time High |
26.57 |
| All Time Low |
0.270139 |
| Ask |
2.52 |
| Ask Size |
2 |
| Average Analyst Rating |
2.0 - Buy |
| Average Daily Volume10 Day |
64,360 |
| Average Daily Volume3 Month |
66,000 |
| Average Volume |
66,000 |
| Average Volume10Days |
64,360 |
| Beta |
1.313 |
| Bid |
1.45 |
| Bid Size |
2 |
| Book Value |
2.2465682 |
| City |
Hamburg |
| Compensation As Of Epoch Date |
1,767,139,200 |
| Country |
Germany |
| Crypto Tradeable |
0 |
| Currency |
USD |
| Current Price |
2.015 |
| Current Ratio |
1.68 |
| Custom Price Alert Confidence |
HIGH |
| Date Short Interest |
1,782,777,600 |
| Day High |
2.025 |
| Day Low |
1.969 |
| Debt To Equity |
55.382 |
| Earnings Call Timestamp End |
1,778,068,800 |
| Earnings Call Timestamp Start |
1,778,068,800 |
| Earnings Timestamp |
1,778,097,600 |
| Earnings Timestamp End |
1,778,097,600 |
| Earnings Timestamp Start |
1,778,097,600 |
| Ebitda |
-16,689,000 |
| Ebitda Margins |
-0.0224 |
| Enterprise To Ebitda |
-42.104 |
| Enterprise To Revenue |
0.943 |
| Enterprise Value |
702,666,112 |
| Eps Forward |
-0.19 |
| Eps Trailing Twelve Months |
-0.62 |
| Esg Populated |
0 |
| Exchange |
NMS |
| Exchange Data Delayed By |
0 |
| Exchange Timezone Name |
America/New_York |
| Exchange Timezone Short Name |
EDT |
| Fifty Day Average |
2.8318 |
| Fifty Day Average Change |
-0.8167999 |
| Fifty Day Average Change Percent |
-0.2884384 |
| Fifty Two Week Change Percent |
-49.2891 |
| Fifty Two Week High |
4.42 |
| Fifty Two Week High Change |
-2.405 |
| Fifty Two Week High Change Percent |
-0.5441176 |
| Fifty Two Week Low |
1.969 |
| Fifty Two Week Low Change |
0.046000123 |
| Fifty Two Week Low Change Percent |
0.023362175 |
| Fifty Two Week Range |
1.969 - 4.42 |
| Financial Currency |
EUR |
| First Trade Date Milliseconds |
1,075,991,400,000 |
| Float Shares |
266,826,580 |
| Forward Eps |
-0.19 |
| Forward P E |
-10.605264 |
| Free Cashflow |
98,592,248 |
| Full Exchange Name |
NasdaqGS |
| Full Time Employees |
4,526 |
| Gmt Off Set Milliseconds |
-14,400,000 |
| Gross Margins |
0.10659 |
| Gross Profits |
79,417,000 |
| Has Pre Post Market Data |
1 |
| Held Percent Insiders |
0.00005 |
| Held Percent Institutions |
0.02151 |
| Implied Shares Outstanding |
355,188,058 |
| Industry |
Drug Manufacturers - Specialty & Generic |
| Industry Disp |
Drug Manufacturers - Specialty & Generic |
| Industry Key |
drug-manufacturers-specialty-generic |
| Ipo Expected Date |
2,021-11-04 |
| Is Earnings Date Estimate |
0 |
| Language |
en-US |
| Last Fiscal Year End |
1,767,139,200 |
| Last Split Date |
1,634,688,000 |
| Last Split Factor |
4:1 |
| Long Business Summary |
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic diseases, and rare diseases. It is also developingcentral nervous system (CNS) and cardiometabolic diseases; and animal and women health. The company has collaboration agreements with Mass General Brigham and Joslin Diabetes Center focusing on cardiometabolic diseases; BMS antiviral; Novo Nordisk cell therapy; University of Oxford; German Cancer Research Center; University Hospital in Hamburg; University of Toronto, Harvard, and Yale; Johns Hopkins University; Ospedale San Raffaele (OSR); and National University of Singapore. In addition, it has a partnership with LAB282, LAB150, beLAB2122, beLAB1407, LAB eN², Danube Labs, VC Amplitude Ventures, LaB eN2, and 65LAB. Further, the company serves pharma and biotechnology companies, academic institutions, patient advocacy groups, and venture capital. Evotec SE has strategic collaboration with Almirall, S.A. for the development of novel therapeutics for severe skin diseases, including a range of immune-mediated inflammatory conditions. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany. |
| Long Name |
Evotec SE |
| Market |
us_market |
| Market Cap |
715,704,000 |
| Market State |
REGULAR |
| Max Age |
86,400 |
| Message Board Id |
finmb_531375 |
| Most Recent Quarter |
1,774,915,200 |
| Net Income To Common |
-193,876,000 |
| Next Fiscal Year End |
1,798,675,200 |
| Non Diluted Market Cap |
758,415,573 |
| Number Of Analyst Opinions |
4 |
| Open |
1.98 |
| Operating Cashflow |
18,713,000 |
| Operating Margins |
-0.29635 |
| Payout Ratio |
0.0 |
| Peg Ratio |
1.42 |
| Phone |
49 40 560 81 0 |
| Previous Close |
2.14 |
| Price Hint |
4 |
| Price To Book |
0.8969236 |
| Price To Sales Trailing12 Months |
0.96062624 |
| Profit Margins |
-0.26022 |
| Quick Ratio |
1.445 |
| Quote Source Name |
Nasdaq Real Time Price |
| Quote Type |
EQUITY |
| Recommendation Key |
buy |
| Recommendation Mean |
2.0 |
| Region |
US |
| Regular Market Change |
-0.125 |
| Regular Market Change Percent |
-5.841121 |
| Regular Market Day High |
2.025 |
| Regular Market Day Low |
1.969 |
| Regular Market Day Range |
1.969 - 2.025 |
| Regular Market Open |
1.98 |
| Regular Market Previous Close |
2.14 |
| Regular Market Price |
2.015 |
| Regular Market Time |
1,784,124,828 |
| Regular Market Volume |
73,613 |
| Return On Assets |
-0.03143 |
| Return On Equity |
-0.24058 |
| Revenue Growth |
-0.217 |
| Revenue Per Share |
2.0975 |
| Sand P52 Week Change |
0.2043345 |
| Sector |
Healthcare |
| Sector Disp |
Healthcare |
| Sector Key |
healthcare |
| Shares Outstanding |
355,188,058 |
| Shares Percent Shares Out |
0.0001 |
| Shares Short |
53,014 |
| Shares Short Previous Month Date |
1,780,012,800 |
| Shares Short Prior Month |
75,029 |
| Short Name |
Evotec SE |
| Short Percent Of Float |
0.0002 |
| Short Ratio |
1.46 |
| Source Interval |
15 |
| Symbol |
EVO |
| Target High Price |
6.813086 |
| Target Low Price |
2.9203844 |
| Target Mean Price |
5.1346946 |
| Target Median Price |
5.402654 |
| Total Cash |
444,763,008 |
| Total Cash Per Share |
1.252 |
| Total Debt |
387,462,016 |
| Total Revenue |
745,038,976 |
| Tradeable |
0 |
| Trailing Annual Dividend Rate |
0.0 |
| Trailing Annual Dividend Yield |
0.0 |
| Trailing Eps |
-0.62 |
| Trailing Peg Ratio |
None |
| Triggerable |
1 |
| Two Hundred Day Average |
3.17055 |
| Two Hundred Day Average Change |
-1.15555 |
| Two Hundred Day Average Change Percent |
-0.36446357 |
| Type Disp |
Equity |
| Volume |
73,613 |
| Website |
https://www.evotec.com |
| Zip |
22,419 |